Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Watabe, Tadashi; Naka, Sadahiro; Tatsumi, Mitsuaki; Kamiya, Takashi; Kimura, Toru; Shintani, Yasushi; Abe, Kaori; Miyake, Tomohiro; Shimazu, Kenzo; Kobayashi, Shogo; Kurokawa, Yukinori; Eguchi, Hidetoshi; Doki, Yuichiro; Inohara, Hidenori; Kato, Hiroki; Mori, Yuriko; Cardinale, Jens; Giesel, Frederik L.

doi:https://doi.org/10.2967/jnumed.123.265486

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Watabe, Tadashi; Naka, Sadahiro; Tatsumi, Mitsuaki et al.

Journal of Nuclear Medicine, 2023, 64(8), 1225-1231

アクセス数:509件（2025-04-28 19:11 集計）

固定URL: https://hdl.handle.net/11094/92496

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
JNuclMed_64_8_1225	pdf	なし	1.01 MB	150	2023.09.08

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
著者	NRID 1000090648932 1000090648932 ORCID 0000-0001-8658-2395 0000-0001-8658-2395 researchmap permalink twosaka2018 twosaka2018 Scopus Author ID 57421862900 57421862900 著者名 Watabe, Tadashi
	NRID 1000060599843 1000060599843 researchmap permalink _sada_ _sada_ 著者名 Naka, Sadahiro
	NRID 1000060397700 1000060397700 ORCID 0000-0003-1778-0421 0000-0003-1778-0421 researchmap permalink mtatsumi mtatsumi Scopus Author ID 7102266657 7102266657 著者名 Tatsumi, Mitsuaki
	NRID 1000080550764 1000080550764 著者名 Kamiya, Takashi
	NRID 1000090580796 1000090580796 ORCID 0000-0003-4504-232X 0000-0003-4504-232X researchmap permalink toru_kimura toru_kimura 著者名 Kimura, Toru
	NRID 1000090572983 1000090572983 researchmap permalink shintani6384 shintani6384 Scopus Author ID 7103142734 7103142734 著者名 Shintani, Yasushi
	NRID 1000080587593 1000080587593 researchmap permalink AbeKaori AbeKaori Scopus Author ID 57189054847 57189054847 著者名 Abe, Kaori
	NRID 1000000636110 1000000636110 ORCID 0000-0002-9362-9822 0000-0002-9362-9822 researchmap permalink tomohiromiyake tomohiromiyake Scopus Author ID 55165894400 55165894400 著者名 Miyake, Tomohiro
	NRID 1000030448039 1000030448039 researchmap permalink _-23f _-23f Scopus Author ID 7005224756 7005224756 著者名 Shimazu, Kenzo
	NRID 1000030452436 1000030452436 researchmap permalink 30452436 30452436 Scopus Author ID 7405376089 7405376089 ORCID 0000-0002-8828-1067 0000-0002-8828-1067 著者名 Kobayashi, Shogo
	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 著者名 Kurokawa, Yukinori
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 著者名 Eguchi, Hidetoshi
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
	NRID 1000000273657 1000000273657 researchmap permalink read0046473 read0046473 Scopus Author ID 7004501837 7004501837 著者名 Inohara, Hidenori
	NRID 1000020448054 1000020448054 researchmap permalink kato-h kato-h Scopus Author ID 55585587900 55585587900 著者名 Kato, Hiroki
	著者名 Mori, Yuriko
	著者名 Cardinale, Jens
	著者名 Giesel, Frederik L.
キーワード等	cancer-associated fibroblast
	fibroblast activation protein
	oncology
	PET
	[18F]FAPI-74
内容	This research was originally published in JNM. Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi et.al. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023, 64(8), 1225-1231. © SNMMI.
抄録	The 18F-labeled fibroblast activation protein inhibitor (FAPI) [18F]FAPI- 74 has the benefit of a higher synthetic yield and better image resolution than 68Ga-labeled FAPI. We preliminarily evaluated the diagnostic performance of [18F]FAPI-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies. Methods: We enrolled 31 patients (17 men and 14 women) with lung cancer (n = 7), breast cancer (n = 5), gastric cancer (n = 5), pancreatic cancer (n = 3), other cancers (n = 5), and benign tumors (n = 6). Twenty-seven of the 31 patients were treatment-naïve or preoperative, whereas recurrence was suspected in the remaining 4 patients. Histopathologic confirmation was obtained for the primary lesions of 29 of the 31 patients. In the remaining 2 patients, the final diagnosis was based on the clinical course. [18F]FAPI-74 PET scanning was performed 60min after the intravenous injection of [18F]FAPI-74 (240631 MBq). The [18F]FAPI-74 PET images were compared between the primary or local recurrent lesions of malignant tumors (n = 21) and nonmalignant lesions (n 5 8: type-B1 thymomas, granuloma, solitary fibrous tumor, and postoperative or posttherapeutic changes). The uptake and number of detected lesions on [18F]FAPI-74 PET were also compared with those on [18F]FDG PET for available patients (n = 19). Results: [18F]FAPI-74 PET showed higher uptake in primary lesions of various cancers than in nonmalignant lesions (median SUVmax, 9.39 [range, 1.83-25.28] vs. 3.49 [range, 2.21-15.58]; P = 0.053), but some of the nonmalignant lesions showed high uptake. [18F]FAPI-74 PET also showed significantly higher uptake than [18F]FDG PET (median SUVmax, 9.44 [range, 2.50-25.28] vs. 5.45 [range, 1.22-15.06] in primary lesions [P 5 0.010], 8.86 [range, 3.51-23.33] vs. 3.84 [range, 1.01-9.75] in lymph node metastases [P 5 0.002], and 6.39 [range, 0.55-12.78] vs. 1.88 [range, 0.73-8.35] in other metastases [P 5 0.046], respectively). In 6 patients, [18F]FAPI-74 PET detected more metastatic lesions than [18F]FDG PET. Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.
出版者	Society of Nuclear Medicine Inc.
収録物名	Journal of Nuclear Medicine
巻(号)	64(8)
ページ	1225-1231
刊行年月	2023-06-02
言語	英語
ハンドルURL	https://hdl.handle.net/11094/92496
PISSN	01615505
eISSN	2159662X
NCID	AA00703684
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.2967/jnumed.123.265486
アクセス権	open access
権利情報	© 2023 by the Society of Nuclear Medicine andMolecular Imaging.
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Journal of Nuclear Medicine. 2023, 64(8), p. 1225-1231
DC.title	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
DC.creator	Watabe, Tadashi
	Naka, Sadahiro
	Tatsumi, Mitsuaki
	Kamiya, Takashi
	Kimura, Toru
	Shintani, Yasushi
	Abe, Kaori
	Miyake, Tomohiro
	Shimazu, Kenzo
	Kobayashi, Shogo
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
	Inohara, Hidenori
	Kato, Hiroki
	Mori, Yuriko
	Cardinale, Jens
	Giesel, Frederik L.
DC.publisher	Society of Nuclear Medicine Inc.
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-06-02
DC.identifier	https://doi.org/10.2967/jnumed.123.265486
DC.subject	cancer-associated fibroblast
	fibroblast activation protein
	oncology
	PET
	[18F]FAPI-74
DC.description	This research was originally published in JNM. Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi et.al. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023, 64(8), 1225-1231. © SNMMI.
DCTERMS.abstract	The 18F-labeled fibroblast activation protein inhibitor (FAPI) [18F]FAPI- 74 has the benefit of a higher synthetic yield and better image resolution than 68Ga-labeled FAPI. We preliminarily evaluated the diagnostic performance of [18F]FAPI-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies. Methods: We enrolled 31 patients (17 men and 14 women) with lung cancer (n = 7), breast cancer (n = 5), gastric cancer (n = 5), pancreatic cancer (n = 3), other cancers (n = 5), and benign tumors (n = 6). Twenty-seven of the 31 patients were treatment-naïve or preoperative, whereas recurrence was suspected in the remaining 4 patients. Histopathologic confirmation was obtained for the primary lesions of 29 of the 31 patients. In the remaining 2 patients, the final diagnosis was based on the clinical course. [18F]FAPI-74 PET scanning was performed 60min after the intravenous injection of [18F]FAPI-74 (240631 MBq). The [18F]FAPI-74 PET images were compared between the primary or local recurrent lesions of malignant tumors (n = 21) and nonmalignant lesions (n 5 8: type-B1 thymomas, granuloma, solitary fibrous tumor, and postoperative or posttherapeutic changes). The uptake and number of detected lesions on [18F]FAPI-74 PET were also compared with those on [18F]FDG PET for available patients (n = 19). Results: [18F]FAPI-74 PET showed higher uptake in primary lesions of various cancers than in nonmalignant lesions (median SUVmax, 9.39 [range, 1.83-25.28] vs. 3.49 [range, 2.21-15.58]; P = 0.053), but some of the nonmalignant lesions showed high uptake. [18F]FAPI-74 PET also showed significantly higher uptake than [18F]FDG PET (median SUVmax, 9.44 [range, 2.50-25.28] vs. 5.45 [range, 1.22-15.06] in primary lesions [P 5 0.010], 8.86 [range, 3.51-23.33] vs. 3.84 [range, 1.01-9.75] in lymph node metastases [P 5 0.002], and 6.39 [range, 0.55-12.78] vs. 1.88 [range, 0.73-8.35] in other metastases [P 5 0.046], respectively). In 6 patients, [18F]FAPI-74 PET detected more metastatic lesions than [18F]FDG PET. Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.
DC.rights	© 2023 by the Society of Nuclear Medicine andMolecular Imaging.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	92496
citation_title	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
citation_author	Watabe, Tadashi
	Naka, Sadahiro
	Tatsumi, Mitsuaki
	Kamiya, Takashi
	Kimura, Toru
	Shintani, Yasushi
	Abe, Kaori
	Miyake, Tomohiro
	Shimazu, Kenzo
	Kobayashi, Shogo
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
	Inohara, Hidenori
	Kato, Hiroki
	Mori, Yuriko
	Cardinale, Jens
	Giesel, Frederik L.
citation_publisher	Society of Nuclear Medicine Inc.
citation_language	英語
citation_date	2023-06-02
citation_journal_title	Journal of Nuclear Medicine
citation_volume	64
citation_issue	8
citation_firstpage	1225
citation_lastpage	1231
citation_doi	https://doi.org/10.2967/jnumed.123.265486
citation_public_url	https://hdl.handle.net/11094/92496

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

閲覧可能ファイル

論文情報

論文詳細を表示